Surprised this had no comments. I liked the presentation professionalism and information. Improved on past presentations informatively, particularly on enrolment clarification in trials.
All eyes on MSB this week I suppose. I'd hope they shelve GvHD if MSB gets the tick. They've demonstrated their similar MOA in the phase 1 to the market and the scale/consistency arguments well known. Sorry to sound callous, but MSB doing it, and its not as lucrative in terms of spend/reward as some of their other avenues of research. Concentrate on DFU (15 to 25% of patients with diabetes mellitus will develop a diabetic foot ulcer during their lifetime). Knee OA and Renal funded so somewhat take care of themselves. CYP's technology useless if this company never gets off the ground commercially.
If MSB does get approved then CYP is stupidly cheap on intellectual property alone, let alone the funded trials it has in progress.
CYP Price at posting:
15.0¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)